These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

717 related items for PubMed ID: 21791944

  • 21. A retrospective study of breast cancer subtypes: the risk of relapse and the relations with treatments.
    Wang Y, Yin Q, Yu Q, Zhang J, Liu Z, Wang S, Lv S, Niu Y.
    Breast Cancer Res Treat; 2011 Nov; 130(2):489-98. PubMed ID: 21837481
    [Abstract] [Full Text] [Related]

  • 22. Prognostic value of breast cancer subtypes on breast cancer specific survival, distant metastases and local relapse rates in conservatively managed early stage breast cancer: a retrospective clinical study.
    Sanpaolo P, Barbieri V, Genovesi D.
    Eur J Surg Oncol; 2011 Oct; 37(10):876-82. PubMed ID: 21824742
    [Abstract] [Full Text] [Related]

  • 23. Clinical features and survival analysis of T1mic, a, bN0M0 breast cancer.
    Li J, Liu X, Tong Z.
    Jpn J Clin Oncol; 2012 Jun; 42(6):471-6. PubMed ID: 22493058
    [Abstract] [Full Text] [Related]

  • 24. Young age is associated with ipsilateral breast tumor recurrence after breast conserving surgery and radiation therapy in patients with HER2-positive/ER-negative subtype.
    Kim HJ, Han W, Yi OV, Shin HC, Ahn SK, Koh BS, Moon HG, You JH, Son BH, Ahn SH, Noh DY.
    Breast Cancer Res Treat; 2011 Nov; 130(2):499-505. PubMed ID: 21853352
    [Abstract] [Full Text] [Related]

  • 25. alphaB-crystallin is a novel predictor of resistance to neoadjuvant chemotherapy in breast cancer.
    Ivanov O, Chen F, Wiley EL, Keswani A, Diaz LK, Memmel HC, Rademaker A, Gradishar WJ, Morrow M, Khan SA, Cryns VL.
    Breast Cancer Res Treat; 2008 Oct; 111(3):411-7. PubMed ID: 17968656
    [Abstract] [Full Text] [Related]

  • 26. Predictors of locoregional outcome in patients receiving neoadjuvant therapy and postmastectomy radiation.
    Wright JL, Takita C, Reis IM, Zhao W, Saigal K, Wolfson A, Markoe A, Moller M, Hurley J.
    Cancer; 2013 Jan 01; 119(1):16-25. PubMed ID: 22736498
    [Abstract] [Full Text] [Related]

  • 27. Semi-quantitative evaluation of estrogen receptor expression is a strong predictive factor of pathological complete response after anthracycline-based neo-adjuvant chemotherapy in hormonal-sensitive breast cancer.
    Petit T, Wilt M, Velten M, Rodier JF, Fricker JP, Dufour P, Ghnassia JP.
    Breast Cancer Res Treat; 2010 Nov 01; 124(2):387-91. PubMed ID: 20824324
    [Abstract] [Full Text] [Related]

  • 28. [Clinical features and prognosis analysis of different breast cancer molecular subtypes].
    Yang Q, Chen J, Li HJ, Yu M, Tian CX, Lü Q.
    Zhonghua Zhong Liu Za Zhi; 2011 Jan 01; 33(1):42-6. PubMed ID: 21575463
    [Abstract] [Full Text] [Related]

  • 29. Prognostic role of a multigene reverse transcriptase-PCR assay in patients with node-negative breast cancer not receiving adjuvant systemic therapy.
    Esteva FJ, Sahin AA, Cristofanilli M, Coombes K, Lee SJ, Baker J, Cronin M, Walker M, Watson D, Shak S, Hortobagyi GN.
    Clin Cancer Res; 2005 May 01; 11(9):3315-9. PubMed ID: 15867229
    [Abstract] [Full Text] [Related]

  • 30. Her2/neu-positive disease does not increase risk of locoregional recurrence for patients treated with neoadjuvant doxorubicin-based chemotherapy, mastectomy, and radiotherapy.
    Buchholz TA, Huang EH, Berry D, Pusztai L, Strom EA, McNeese MD, Perkins GH, Schechter NR, Kuerer HM, Buzdar AU, Valero V, Hunt KK, Hortobagyi GN, Sahin AA.
    Int J Radiat Oncol Biol Phys; 2004 Aug 01; 59(5):1337-42. PubMed ID: 15275718
    [Abstract] [Full Text] [Related]

  • 31. Prognostic value of pathologic complete response after primary chemotherapy in relation to hormone receptor status and other factors.
    Guarneri V, Broglio K, Kau SW, Cristofanilli M, Buzdar AU, Valero V, Buchholz T, Meric F, Middleton L, Hortobagyi GN, Gonzalez-Angulo AM.
    J Clin Oncol; 2006 Mar 01; 24(7):1037-44. PubMed ID: 16505422
    [Abstract] [Full Text] [Related]

  • 32. Breast conservation therapy: the influence of molecular subtype and margins.
    Demirci S, Broadwater G, Marks LB, Clough R, Prosnitz LR.
    Int J Radiat Oncol Biol Phys; 2012 Jul 01; 83(3):814-20. PubMed ID: 22208971
    [Abstract] [Full Text] [Related]

  • 33. Triple-negative phenotype is of adverse prognostic value in patients treated with dose-dense sequential adjuvant chemotherapy: a translational research analysis in the context of a Hellenic Cooperative Oncology Group (HeCOG) randomized phase III trial.
    Skarlos P, Christodoulou C, Kalogeras KT, Eleftheraki AG, Bobos M, Batistatou A, Valavanis C, Tzaida O, Timotheadou E, Kronenwett R, Wirtz RM, Kostopoulos I, Televantou D, Koutselini E, Papaspirou I, Papadimitriou CA, Pectasides D, Gogas H, Aravantinos G, Pavlidis N, Arapantoni P, Skarlos DV, Fountzilas G.
    Cancer Chemother Pharmacol; 2012 Feb 01; 69(2):533-46. PubMed ID: 21901395
    [Abstract] [Full Text] [Related]

  • 34. Gene expression of estrogen receptor, progesterone receptor and microtubule-associated protein Tau in high-risk early breast cancer: a quest for molecular predictors of treatment benefit in the context of a Hellenic Cooperative Oncology Group trial.
    Pentheroudakis G, Kalogeras KT, Wirtz RM, Grimani I, Zografos G, Gogas H, Stropp U, Pectasides D, Skarlos D, Hennig G, Samantas E, Bafaloukos D, Papakostas P, Kalofonos HP, Pavlidis N, Fountzilas G.
    Breast Cancer Res Treat; 2009 Jul 01; 116(1):131-43. PubMed ID: 18668363
    [Abstract] [Full Text] [Related]

  • 35. Risk of locoregional recurrence by receptor status in breast cancer patients receiving modern systemic therapy and post-mastectomy radiation.
    Panoff JE, Hurley J, Takita C, Reis IM, Zhao W, Sujoy V, Gomez CR, Jorda M, Koniaris L, Wright JL.
    Breast Cancer Res Treat; 2011 Aug 01; 128(3):899-906. PubMed ID: 21475999
    [Abstract] [Full Text] [Related]

  • 36. [Clinical characteristics and prognosis of different subtypes of breast cancer].
    Yuan ZY, Wang SS, Zhu MQ, Zheng L, Luo WB, Zhou ZM, Guan ZZ.
    Zhonghua Zhong Liu Za Zhi; 2008 Jun 01; 30(6):456-61. PubMed ID: 19024523
    [Abstract] [Full Text] [Related]

  • 37. Molecular subtyping of early-stage breast cancer identifies a group of patients who do not benefit from neoadjuvant chemotherapy.
    Glück S, de Snoo F, Peeters J, Stork-Sloots L, Somlo G.
    Breast Cancer Res Treat; 2013 Jun 01; 139(3):759-67. PubMed ID: 23756626
    [Abstract] [Full Text] [Related]

  • 38. [Combined surgery and radiotherapy in the treatment of ductal carcinoma in situ of the breast: preliminary results of the Hungarian multicenter prospective randomised study].
    Polgár C, Orosz Z, Kahán Z, Gábor G, Jani N, Cserni G, Hadijev J, Kulka J, Sulyok Z, Boross G, Lázár G, László Z, Diczházi C, Udvarhelyi N, Szabó E, Péntek Z, Major T, Fodor J.
    Magy Onkol; 2008 Sep 01; 52(3):269-77. PubMed ID: 18845497
    [Abstract] [Full Text] [Related]

  • 39. Prognostic value of molecular subtypes, ki67 expression and impact of postmastectomy radiation therapy in breast cancer patients with negative lymph nodes after mastectomy.
    Selz J, Stevens D, Jouanneau L, Labib A, Le Scodan R.
    Int J Radiat Oncol Biol Phys; 2012 Dec 01; 84(5):1123-32. PubMed ID: 22572073
    [Abstract] [Full Text] [Related]

  • 40. Outcome prediction for estrogen receptor-positive breast cancer based on postneoadjuvant endocrine therapy tumor characteristics.
    Ellis MJ, Tao Y, Luo J, A'Hern R, Evans DB, Bhatnagar AS, Chaudri Ross HA, von Kameke A, Miller WR, Smith I, Eiermann W, Dowsett M.
    J Natl Cancer Inst; 2008 Oct 01; 100(19):1380-8. PubMed ID: 18812550
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 36.